SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the
Sale of Juno Therapeutics, Inc. to Celgene Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Juno Therapeutics, Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ:JUNO)
stock prior to January 22, 2018 .
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into
the fairness of the sale of Juno Therapeutics to Celgene Corporation (NASDAGS:CELG) for $87 per share. To learn more
about the action and your rights, go to:
http://www.zlk.com/mna/juno-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost
or obligation to you.
The complaint concerns whether the Board of Juno Therapeutics breached their fiduciary duties to stockholders by failing to
adequately shop the Company before agreeing to enter into this transaction, and whether Celgene Corporation is underpaying for Juno
Therapeutics shares, thus unlawfully harming Juno Therapeutics shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's
attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors
throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved
shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior
results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180122006039/en/